NCT00148876已完成3 期
A Multicenter Randomized Phase III Study to Compare Capecitabine Alone or in Combination With Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer and Progression After Previous Treatment With Trastuzumab
German Breast Group1 个研究点 分布在 1 个国家目标入组 482 人开始时间: 2003年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 482
- 试验地点
- 1
- 主要终点
- Any progression of disease or disease related death of a patient
研究概览
简要总结
This study is done in patients having Breast Cancer with metastasis (patients with positive receptor HER2) whose disease progressed after receiving Trastuzumab.
The primary objective of this study is to compare the time until disease progression between the Treatment Arm CAPECITABINE and the Treatment Arm CAPECITABINE + TRASTUZUMAB
The study has also other secondary and tertiary objectives.
详细描述
Trial design:
Prospective, multi-center, controlled, non blinded, randomized phase III Study
Treatment:
Patients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumab are being randomized to either:
A. Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression * and discontinuation of Trastuzumab
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements.
- •Pathologically confirmed carcinoma of the breast.
- •Locally advanced or metastatic stage of disease not suitable for surgery or radiotherapy alone.
- •HER2-overexpression of the primary or metastatic tumor tissue detected by immunohistochemistry (DAKO) 3+ or gene namplification detected by FISH. HER2-positive primary tumours with HER2-negative metastasis can be included.
- •Disease progression during or after previous chemotherapy and trastuzumab treatment as follows (Trastuzumab has to be given previously for at least 12 weeks, treatment free interval of trastuzumab for a maximum of 6 weeks):
- •Taxanes + trastuzumab given as adjuvant therapy
- •Taxanes + trastuzumab given as first line therapy for palliation
- •Trastuzumab given as first line therapy for palliation alone or in combination with chemotherapeutic agents other than capecitabine or taxanes
- •No more than 1 chemotherapy for palliation (max. Adriamycin dose < or = 400 mg/m²; Epirubicin < or = 600 mg/m²)
- •Patients must have either measurable or nonmeasurable target lesions according to the RECIST criteria (see Appendix 6)
- •At least 4 weeks since radiotherapy, with full recovery. The measurable disease must be completely outside the radiation portal or there must be pathologic proof of progressive disease
- •At least 4 weeks since major surgery with full recovery.
- •Complete radiology and tumor measurement work up within 4 weeks prior to registration:
- •Karnofsky performance status evaluation > or = 60%
- •Age >18 years.
- •Absolute neutrophil count > or =1,500 cells/microL, platelet count > or =100,000 cells/microL.
- •Bilirubin < or = 2x the upper limit of normal for the institution (ULN); elevation of transaminases and alkaline phosphatase < 2.5x ULN or <5x ULN for patients with liver metastases.
- •Creatinine < or = 2.0 mg/dl.
- •Left ventricular ejection fraction (LVEF) by cardiac ultrasound of > or = 50%.
- •If of childbearing potential, pregnancy test is negative. In addition the patient agrees to use an effective method to avoid pregnancy for the duration of the study.
- •Exclusion criteria:
- •Known hypersensitivity reaction to the compounds or incorporated substances or known dihydropyrimidine dehydrogenase deficiency.
- •Concurrent immunotherapy or hormonal therapy (antihormonal, contraceptive and/or replacement therapy). Bisphosphonates may be continued.
- •Parenchymal brain metastases, unless adequately controlled by surgery and/or radiotherapy with complete resolution of symptoms and of all steroids.
- •Life expectancy of less than 3 months.
- •Serious intercurrent medical or psychiatric illness that may interfere with the planned treatment (including severe pulmonary conditions, AIDS and serious active infection).
- •History of congestive heart failure or other significant uncontrolled cardiac disease.
- •History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer.
- •Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.
- •Treatment with sorivudine or derivates e.g. brivudin
- •Pregnant or nursing women.
- •Male patients.
- •The patient must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre which could be the Principal or Co- investigator's site.
排除标准
- 未提供
研究组 & 干预措施
Capecitabine
Active Comparator
Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression and discontinuation of Trastuzumab.
干预措施: Capecitabine (Drug)
Capecitabine and Trastuzumab
Experimental
Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression + Trastuzumab 6 mg/kg body weight every 3 weeks i.v. as a 90 min infusion until progression
干预措施: Capecitabine (Drug)
Capecitabine and Trastuzumab
Experimental
Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression + Trastuzumab 6 mg/kg body weight every 3 weeks i.v. as a 90 min infusion until progression
干预措施: Trastuzumab (Drug)
结局指标
主要结局
Any progression of disease or disease related death of a patient
次要结局
- Any response documented according to the RECIST Criteria
- Time from CR or PR until progression of disease or death due to any cause
- Any response and stable disease of >24 weeks duration documented according to the RECIST Criteria
- Any grade III/IV toxicity (NCI-CTC version2.0).Premature treatment discontinuation
- Any death of a patient
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast CancerBreast CancerNCT00293540International Breast Cancer Research Foundation249
已完成
3 期
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast CancerBreast CancerNCT00950300Hoffmann-La Roche596
已完成
3 期
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerHER-2 Positive Breast CancerMetastatic NeoplasmNCT02492711MacroGenics624
终止
3 期
A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast CancerTriple Negative Breast CancerNCT05134194Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
终止
3 期
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast CancerBreast NeoplasmsNeoplasm MetastasisNCT00083993Wyeth is now a wholly owned subsidiary of Pfizer1,236